Clinical Trial

A Study of NH280105 in Healthy Adult Participants

Completed Phase 1
View on ClinicalTrials.gov →
Summary
This is a Phase 1, randomized, double-blinded, placebo-controlled, single ascending dose (SAD) and multiple ascending dose (MAD) study to assess the safety, tolerability, pharmacokinetics (PK), and pharmacodynamics (PD) of NH280105 in healthy volunteers. In addition, this study will evaluate the effects of food on NH280105 under a two-period study setting.
Protocol Amendment History 3 amendments
This ClinicalTrials.gov record has been amended 3 times since 2025-03-05; most recent amendment 2026-01-13.
Status change: Recruiting → Completed 2025-12-10
Status change: Not Yet Recruiting → Recruiting 2025-06-23
Trial Details
NCT Number NCT06870058
Lead Sponsor Jiangsu Nhwa Pharmaceutical Co., Ltd.
Conditions Alzheimer Disease
Enrollment 32 participants
Start Date 2025-03-12
Primary Completion 2025-11-13 (estimated)
Study Completion 2025-11-13 (estimated)
Updated on ClinicalTrials.gov 2026-01-15